[ad_1]
[사진 = 연합뉴스]The government announced that it does not require approval from the United States Food and Drug Administration (FDA) to bring AstraZeneca’s COVID-19 vaccine to Korea.
“The US FDA is an American agency and Korea” We will go through the decision process of the Ministry of Food and Drug Safety. ”
Since the approval of the AstraZeneca vaccine by the US FDA is delayed, it has made it clear that the government is not affected by concerns that it will be difficult to obtain this vaccine in the first quarter of next year. in Corea.
An official from the Ministry of Food and Drug Safety also said: “When a permit application is received for a product, we will fully review the safety and efficacy and decide whether to independently approve it.”
Previously, the government insured a total of 44 million vaccines, including 10 million people through the COVAX facility, an international project for the joint purchase and distribution of vaccines, and 34 million through individual negotiations with global pharmaceutical companies. You have a plan to introduce it sequentially from the quarter.
A total of four pharmaceutical companies that have signed a contract and a pre-purchase agreement are AstraZeneca, Pfizer, Johnson & Johnson-Jansen and Modena.
When asked if the supply of the Pfizer vaccine would be difficult because the supply of the Pfizer vaccine was in short supply that day, Jun-wook Kwon, second deputy head of headquarters, said: “We will try to ensure safe vaccination in a fast time “. The timing of vaccination can vary. ”
As for ensuring the quantity through COVAX, “the goal is to supply 20% of the total population in 2021. Even if the quantity is insufficient, it is being discussed to supply at least 3% to each country first to protect the high risk group “There is,” he said, “I will announce it again when some conclusions are made.”
[조성신 기자 [email protected]][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
